Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study.
Jiayu WangYunjiang LiuQingyuan ZhangWei LiJifeng FengXiaojia WangJianmin FangYiqun HanBinghe XuPublished in: Cancer communications (London, England) (2024)
DV demonstrated promising efficacy in HER2-overexpression and HER2-low ABC, with a favorable safety profile at 2.0 mg/kg Q2W.